Skip to Content

TRIOMEL 7 G/L NITROGEN 1140 KCAL/L EMULSION FOR INFUSION

Active substance(s): ALANINE / ARGININE / ASPARTIC ACID / GLUCOSE MONOHYDRATE / GLUTAMIC ACID / GLYCINE / HISTIDINE / ISOLEUCINE / LEUCINE / LYSINE ACETATE / METHIONINE / OLIVE OIL REFINED / PHENYLALANINE / PROLINE / REFINED SOYBEAN OIL / SERINE / THREONINE / TRYPTOPHAN / TYROSINE / VALINE

PDF options:  View Fullscreen   Download PDF

PDF Transcript

1

BE-30-02-812

Date:
Date:

Comments:

Sign:
Sign:

In all cases, your doctor will base his/her decision on whether you should receive this medicine on
factors such as your age, weight, and medical condition, together with the results of any test performed.

Date: 10 MAY 2017

In premature neonates, infants, and children less than 2 years old.
If you are hypersensitive (allergic) to egg, soybean or peanut proteins or to any other ingredient.
If your body has problems using certain amino acids.
If you have an especially high level of fats in your blood.
If you have hyperglycemia (too much sugar in your blood).

Version: 01







Artworker: Donovan Fontesse.

TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion must not be used:

ARTWORK DESIGN CENTRE

2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion
for infusion is administered

Errors: Yes / No PR2:

TRIOMEL must only be used under medical supervision.

Errors: Yes / No PR1:

TRIOMEL is used to provide nutrition to adults and children greater than 2 years of age by a tube into a
vein when normal feeding by mouth is not suitable.

Draft: 02

One chamber contains a glucose solution, the second one contains a lipid emulsion and the third one
contains an amino acid solution.

(and pages ___ to ___ for TIL)

FOR SUBMISSION

TRIOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers.

Applicable for pages ___ to ___

1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and
what it is used for

Date

1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for
2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is
administered
3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used
4. Possible side effects
5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored
6. Contents of the pack and other information

DRAFT

What is in this leaflet:

Signature

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• If you get any side effect, talk to your doctor or nurse. This includes any side effects not listed in
this leaflet. See section 4.

Name

Read all of this leaflet carefully before you will be administered this medicine because it contains
important information for you.

Country

TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

DRAFT
EMEA ARTWORK DESIGN CENTRE

b

Warnings and precautions
Talk to your doctor or nurse before TRIOMEL is administered to you.
If you are given total parenteral nutrition (TPN) solutions too fast this may result in injury or death.
The infusion must be stopped immediately if any abnormal signs or symptoms of an allergic reaction
(such as sweating, fever, chills, headache, skin rashes, or difficulty breathing) develop. This medicinal
product contains soybean oil and egg phosphatide. Soybean and egg proteins may cause hypersensitivity
reactions. Cross-allergic reactions between soybean and peanut proteins have been observed.

DRAFT

During the infusion if you notice pain, burning or swelling at the infusion site, or leakage of the infusion,
tell your doctor or nurse. The administration will be stopped immediately and restarted in another vein.
If your blood sugar gets too high, your doctor should adjust the rate of TRIOMEL delivery or give you
medication to control your blood sugar (insulin).

Date:
Date:

Reduced ability of the body to remove the fats contained in this medicine may result in a “fat overload
syndrome” (See Section 4 – Possible Side Effects).

TRIOMEL may only be administered via a tube (catheter) into a large vein in your chest (central vein).

If your child is under 18 years old, special care will be taken to give him/her the correct dosage.
Increased precautions will also be taken because of the greater sensitivity of children to the risk of
infection. Vitamin and trace element supplementation is always required. Paediatric formulations must
be used.

2

BE-30-02-812

Version: 01
Sign:
Sign:

Children and adolescents

(and pages ___ to ___ for TIL)
Applicable for pages ___ to ___

FOR SUBMISSION

To check the effectiveness and ongoing safety of the administration, your doctor will perform clinical and
laboratory tests while you are receiving this medicine. If you are given this medicine for several weeks,
your blood will be monitored on a regular basis.

Date

DRAFT
Signature

Your doctor should be aware of:
• a severe kidney problem. You also must inform your doctor if you are on dialysis (artificial kidney)
or if you have another form of blood cleaning treatment
• a severe liver problem
• a blood clotting problem
• adrenal glands that are not working properly (adrenal insufficiency). The adrenal glands are
triangle-shaped glands located on top of your kidneys.
• heart failure
• lung disease
• a build up of water in your body (hyperhydration)
• not enough water in your body (dehydration)
• high blood sugar (diabetes mellitus) that you are not being treated for
• a heart attack or shock due to a sudden heart failure
• a severe metabolic acidosis (when the blood is too acidic)
• a generalised infection (septicaemia)
• coma.

Name

The balance of water and salt in your body and metabolic disorders will be corrected before starting
the infusion. Your doctor will monitor your condition while you receive this medicine and may change
the dosage or give you additional nutrients, such as vitamins, electrolytes, and trace elements, if he/she
feels they are appropriate.

Country

If you are severely malnourished such that you need to receive feedings by vein, your doctor should start
the treatment slowly. Also, your doctor should monitor you closely to prevent sudden changes in your
fluid, vitamin, electrolyte and mineral levels.

EMEA ARTWORK DESIGN CENTRE

Certain medications and illnesses can increase the risk of developing infection or sepsis (bacteria in the
blood). There is a particular risk of infection or sepsis when a tube (intravenous catheter) is placed in
your vein. Your doctor will carefully watch you for any signs of infection. Patients who require parenteral
nutrition (giving nutrition through a tube in your vein) may be more likely to develop infections from their
medical conditions. Using aseptic (“germ-free”) techniques when placing and caring for the catheter and
when making the nutritional formula (TPN) can reduce the risk of infection.

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

Difficulty breathing could also be a sign that small particles have formed, blocking blood vessels in the
lungs (pulmonary vascular precipitates). If you experience any difficulty breathing, tell your doctor or
nurse. They will decide a course of action to be taken.

Other medicines and TRIOMEL
Tell your doctor if you are taking or using, have recently taken or used or might take or use any other
medicines.
Simultaneous absorption of other medicinal products is not a contraindication, generally. If you take
other medicinal products, with or without medical prescription, you should inform your doctor in advance
to check compatibility.
TRIOMEL must not be administered simultaneously with blood through the same infusion tubing.

DRAFT

TRIOMEL should be at room temperature before use.
TRIOMEL is for single use only.
The infusion of 1 bag usually lasts between 12 and 24 hours.

Dosage – Adults
Your doctor will specify a flow rate corresponding to your needs and clinical condition.
The prescription may be continued for as long as it is needed, depending upon your clinical condition.

Dosage – Children greater than two years of age and adolescents
The doctor will decide the dose and for how long the medication will be given. This will depend on age,
weight, height, medical condition and the ability of the body to break down and use the ingredients in
TRIOMEL.

If the dose given is too high or the infusion is too fast, the amino acid content may make your blood
too acidic, and signs of hypervolaemia (increase of circulating blood volume) may occur. The glucose
levels in your blood and urine may increase, hyperosmolar syndrome (excessive blood viscosity) may
develop, and the lipid content may increase the level of triglycerides in your blood. Receiving a volume
of TRIOMEL that is too large may cause nausea, vomiting, chills and electrolyte disturbances. In such
situations, the infusion must be stopped immediately.

Date:
Date:

If you have been administered more TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion
for infusion than you should

In some severe cases, your doctor may have to give you temporary renal dialysis to help your kidneys
eliminate the excess product.
To prevent these events occurring, your doctor will regularly monitor your condition and test your blood
parameters.

Version: 01
Sign:
Sign:

If you have any further questions on the use of this product, ask your doctor.

3

BE-30-02-812

(and pages ___ to ___ for TIL)
Applicable for pages ___ to ___

It is an emulsion for infusion, to be administered via a tube (catheter) into a vein in your chest.

FOR SUBMISSION

TRIOMEL should only be given in adults and children greater than 2 years of age.

Date

Dosage

DRAFT

3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used

Signature

TRIOMEL may be considered during pregnancy and breastfeeding, if necessary.

Name

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before taking this medicine.

Country

Pregnancy, breast-feeding and fertility

EMEA ARTWORK DESIGN CENTRE

The lipids contained in this emulsion may interfere with the results of certain laboratory tests if the
blood sample is taken before the lipids have been eliminated from your bloodstream (these are generally
eliminated after a period of 5 to 6 hours without receiving lipids).

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

The olive and soybean oils present in TRIOMEL contain vitamin K. This does not normally affect blood
thinning medicines (anticoagulants) like coumarin. However, if you take anticoagulant medicines you
should tell your doctor.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any changes in the way you feel during or after the treatment, tell your doctor or nurse right
away.
The tests your doctor will perform while you are taking the medicine should minimise the risk of side
effects.

DRAFT

4

BE-30-02-812

(and pages ___ to ___ for TIL)
Applicable for pages ___ to ___

FOR SUBMISSION
Date

DRAFT
Signature

Name

Date:
Date:

Country

Version: 01
Sign:
Sign:

The following side effects have been reported with similar parenteral nutrition products:
Frequency – Very rare: may affect up to 1 in 10,000 people
• Reduced ability to remove the lipids (fat overload syndrome) associated with sudden and abrupt
worsening of the patient’s medical condition. The following signs of fat overload syndrome are
usually reversible when the lipid emulsion infusion is stopped:
– Fever
– Reduction in red blood cells which can make the skin pale and cause weakness or
breathlessness (anaemia)
– Low white blood cell count, which can increase the risk of infection (leukopenia)
– Low platelet count which can increase the risk of bruising and/or bleeding (thrombocytopenia)
– Coagulation disorders which effect the ability of the blood to clot
– High levels of fats in the blood (hyperlipidaemia)
– Liver fatty infiltration (hepatomegaly)
– Worsening liver function
– Central nervous system manifestations (e.g. Coma).
Frequency – Not known: frequency cannot be estimated from the available data
• Allergic reactions
• Abnormal blood test results for liver function
• Problems with the elimination of bile (cholestasis)
• Increase in the size of the liver (hepatomegaly)
• Icterus (jaundice)
• Decrease in the number of platelets (thrombocytopenia)
• Increased nitrogen levels in the blood (azotemia)
• Elevated liver enzymes
• Formation of small particles which may lead to blockage of blood vessels in the lungs (pulmonary
vascular precipitates) resulting in pulmonary vascular embolism and difficulty breathing
(respiratory distress).

EMEA ARTWORK DESIGN CENTRE

The following side effects have been reported with TRIOMEL:
Frequency – Common: may affect up to 1 in 10 people
• Fast heart rate (tachycardia)
• Loss of appetite (anorexia)
• Increased level of fat in the blood (hypertriglyceridemia)
• Abdominal pain
• Diarrhoea
• Nausea
• Increased blood pressure (hypertension)
Frequency – Not known: frequency cannot be estimated from the available data
• Leakage of the infusion to the surrounding tissue (extravasation) which may result at infusion site
level in pain, irritation, swelling/oedema, redness (erythema)/warmth, death of the tissue cells
(skin necrosis) or blisters

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

If any abnormal signs or symptoms of an allergic reaction develop, such as sweating, fever, chills,
headache, skin rashes, or breathing difficulties, the infusion should be stopped immediately.

Reporting of side effects

Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion contains
The active substances for each bag of the reconstituted emulsion are 11.1% (corresponding to
11.1 g/100 mL) L-amino acid solution (alanine, arginine, glycine, histidine, isoleucine, leucine, lysine
(as lysine acetate), methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine,
aspartic acid, glutamic acid), 20% (corresponding to 20 g/100 mL) lipid emulsion (refined olive oil
and refined soybean oil), and 35% (corresponding to 35 g/100 mL) glucose solution (as glucose
monohydrate).
Lipid emulsion
compartment

Amino acid solution
compartment

Glucose solution
compartment

Purified egg phosphatide,
glycerol, sodium oleate, sodium
hydroxide (for pH adjustment),
water for injection

Glacial acetic acid
(for pH adjustment), water for
injection

Hydrochloric acid
(for pH adjustment), water for
injection

Date:
Date:

The other ingredients are:

TRIOMEL is an emulsion for infusion packaged in a 3-compartment bag. One compartment contains
a lipid emulsion, another compartment an amino acid solution and the third compartment a glucose
solution. These compartments are separated by nonpermanent seals. Before administration, the content
of the compartments need to be mixed by rolling the bag onto itself, starting at the top of the bag until
the peal seal is open.

Appearance prior to reconstitution:

• The amino acid and glucose solutions are clear, colourless, or slightly yellow.
• The lipid emulsion is homogenous with a milky appearance.
5

BE-30-02-812

Version: 01
Sign:
Sign:

What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion looks like and
contents of the pack

(and pages ___ to ___ for TIL)
Applicable for pages ___ to ___

Store in the overpouch.

FOR SUBMISSION

Do not freeze.

Date

Do not use this medicine after the expiry date that is stated on the container and the outer packaging
(MM/YYYY). The expiry date refers to the last day of that month.

DRAFT

Keep this medicine out of the sight and reach of children.

Signature

5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored

Name

United Kingdom:
Via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard

Country

Republic of Ireland:
HPRA Pharmacovigilance,
Earlsfort Terrace,
IRE – Dublin 2.
Tel: +353 1 6764971,
Fax: +353 1 6762517,
Website: www.hpra.ie;
E-mail: medsafety@hpra.ie

DRAFT
ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

Malta
ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal

EMEA ARTWORK DESIGN CENTRE

If you get any side effect, talk to your doctor or nurse. This includes any possible side effect not listed in
this leaflet. You can also report side effects directly (see details below). By reporting side effects you can
help provide more information on the safety of this medicine.

Appearance after reconstitution: homogeneous milk-like emulsion.
The 3-compartment bag is a multilayer plastic bag. The inner (contact) layer of the bag material is
designed to be compatible with the constituents and authorised additives.
To prevent contact with oxygen contained in the air, the bag is packaged in an oxygen barrier overpouch
with an oxygen absorber sachet.

Pack sizes
1,000 mL bag: 1 carton with 6 bags
1,500 mL bag: 1 carton with 4 bags
2,000 mL bag: 1 carton with 4 bags
1 bag of 1,000 mL, 1,500 mL and 2,000 mL

DRAFT

ZentroOLIMEL 4,4 %
Olimel 4,4%
Olimel N7
Triomel 7g/l nitrogen 1140 kcal/l

This leaflet was last revised in 06/2017.

For information about TRIOMEL or to request this
leaflet in formats such as audio or large print
please contact the Marketing Authorisation Holder:
Tel: +44 (0)1635 206345

Version: 01
Sign:
Sign:

Date:
Date:

Baxter and Triomel are trademarks of Baxter international Inc.

6

BE-30-02-812

(and pages ___ to ___ for TIL)
Applicable for pages ___ to ___

Austria:
Germany:
Denmark, Iceland, Sweden, Norway, Finland:
The United Kingdom, Ireland, Malta:

FOR SUBMISSION

OLIMEL N7

In some countries it is registered under a different trade name, as described below:

Date

France, Portugal, Estonia, Poland, Lithuania, Bulgaria,
Romania, Latvia, Belgium, Spain, The Netherlands,
Luxemburg, Slovenia, Italy, Greece, Cyprus:

DRAFT

This medicinal product is authorised in the Member States of the EEA under the following names:

Signature

BAXTER S.A.
BOULEVARD RENE BRANQUART, 80
7860 LESSINES
BELGIUM

Name

Manufacturer

Country

Baxter Healthcare Limited
Caxton Way, Thetford,
Norfolk, IP24 3SE
United Kingdom

EMEA ARTWORK DESIGN CENTRE

Marketing Authorisation Holder

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

Not all pack sizes may be marketed.

The following information is intended for medical
or healthcare professionals only:
TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion
Pharmacotherapeutic group: Solutions for parenteral nutrition/combinations
ATC code: B05 BA10.

DRAFT

800 mL

20% Lipid emulsion
(corresponding to 20 g/100 mL)

200 mL

300 mL

400 mL

Composition of the reconstituted emulsion after mixing the contents of the 3 compartments:
Active substances

1,000 mL

1,500 mL

2,000 mL

Refined olive oil + refined soybean oila

40.00 g

60.00 g

80.00 g

Alanine

6.41 g

9.61 g

12.82 g

Arginine

4.34 g

6.51 g

8.68 g

Aspartic acid

1.28 g

1.92 g

2.56 g

Glutamic acid

2.21 g

3.32 g

4.42 g

Glycine

3.07 g

4.60 g

6.14 g

Histidine

2.64 g

3.97 g

5.29 g

Isoleucine

2.21 g

3.32 g

4.42 g

Leucine

3.07 g

4.60 g

6.14 g

Lysine
(equivalent to lysine acetate)

3.48 g
(4.88 g)

5.23 g
(7.31 g)

6.97 g
(9.75 g)

Methionine

2.21 g

3.32 g

4.42 g

Phenylalanine

3.07 g

4.60 g

6.14 g

Proline

2.64 g

3.97 g

5.29 g

Serine

1.75 g

2.62 g

3.50 g

Threonine

2.21 g

3.32 g

4.42 g

Tryptophan

0.74 g

1.10 g

1.47 g

Tyrosine

0.11 g

0.17 g

0.22 g

Valine

2.83 g

4.25 g

5.66 g

140.00 g
(154.00 g)

210.00 g
(231.00 g)

280.00 g
(308.00 g)

Glucose anhydrous
(equivalent to glucose monohydrate)

Version: 01
Sign:
Sign:

a: Mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%)
corresponding to a ratio essential fatty acids/total fatty acids of 20%.

7

BE-30-02-812

Applicable for pages ___ to ___

600 mL

FOR SUBMISSION

400 mL

Date

11.1% Amino acid solution
(corresponding to 11.1 g/100 mL)

DRAFT

800 mL

Signature

600 mL

Name

2,000 mL

400 mL

Date:
Date:

1,500 mL

35% Glucose solution
(corresponding to 35 g/100 mL)

Country

Contents per bag
1,000 mL

EMEA ARTWORK DESIGN CENTRE

Each bag contains a glucose solution, a lipid emulsion and an amino acid solution.

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

TRIOMEL is presented in the form of a 3-compartment bag.

(and pages ___ to ___ for TIL)

A. QUALITATIVE AND QUANTITATIVE COMPOSITION

The excipients are:
Lipid emulsion compartment

Amino acid solution
compartment

Glucose solution
compartment

Purified egg phosphatide,
glycerol, sodium oleate, sodium
hydroxide (for pH adjustment),
water for injection

Glacial acetic acid
(for pH adjustment), water for
injection

Hydrochloric acid
(for pH adjustment), water for
injection

DRAFT

Nutritional intakes of reconstituted emulsion for each of the bag sizes:

10.5 g

14.0 g

140.0 g

210.0 g

280.0 g

1,140 kcal

1,710 kcal

2,270 kcal

Non-protein calories

960 kcal

1,440 kcal

1,920 kcal

Glucose calories

560 kcal

840 kcal

1,120 kcal

Lipid caloriesa

400 kcal

600 kcal

800 kcal

Energy:
Total calories approx.

Non-protein calories/nitrogen ratio

137 kcal/g

137 kcal/g

137 kcal/g

Glucose/lipid calories ratio

58/42

58/42

58/42

Lipid/total calories

35%

35%

35%

Phosphateb

3.0 mmol

4.5 mmol

6.0 mmol

Acetate

31 mmol

46 mmol

62 mmol

Electrolytes:

pH
Osmolarity

6.4

6.4

6.4

1,220 mosm/L

1,220 mosm/L

1,220 mosm/L

a: Includes calories from purified egg phosphatide
b: Includes phosphate provided by the lipid emulsion

B. POSOLOGY AND METHOD OF ADMINISTRATION
Posology

In adults
The dosage depends on the patient’s energy expenditure, clinical status, body weight, and the ability
to metabolise the constituents of TRIOMEL, as well as additional energy or proteins provided
orally/enterally; therefore, the bag size should be chosen accordingly.
The average daily requirements are:
– 0.16 to 0.35 g nitrogen/kg body weight (1 to 2 g of amino acids/kg), depending on the patient’s
nutritional status and degree of catabolic stress,
– 20 to 40 kcal/kg,
– 20 to 40 mL fluid/kg, or 1 to 1.5 mL per expended kcal.
For TRIOMEL, the maximal daily dose is defined by total caloric intake, 40 kcal/kg provided in a volume
of 35 mL/kg, corresponding to 1.5 g/kg amino acids, 4.9 g/kg glucose, and 1.4 g/kg lipids. For a 70 kg
patient, this would be equivalent to 2,450 mL TRIOMEL per day, resulting in an intake of 108 g amino
acids, 343 g glucose, and 98 g lipids (i.e., 2,352 non-protein kcal and 2,793 total kcal).
BE-30-02-812
8

Version: 01
Sign:
Sign:

The maximum daily dose mentioned below should not be exceeded. Due to the static composition of
the multi-chamber bag, the ability to simultaneously meet all nutrient needs of the patient may not
be possible. Clinical situations may exist where patients require amounts of nutrients varying from
the composition of the static bag. In this situation any volume (dose) adjustments must take into
consideration the resultant effect this will have on the dosing of all other nutrient components of
TRIOMEL. For example, paediatric patients may require greater than 0.2 mmol/kg/day of phosphate. In
those situations, health care professionals may consider adjusting the volume (dose) of TRIOMEL in order
to meet these increased requirements.

Date:
Date:

TRIOMEL is not recommended for use in children less than 2 years of age due to inadequate composition
and volume (see sections 4.4; 5.1 and 5.2 of the SmPC).

(and pages ___ to ___ for TIL)

7.0 g

Glucose

Applicable for pages ___ to ___

Nitrogen

Date

88.6 g

DRAFT

66.4 g

Signature

80 g

44.3 g

FOR SUBMISSION

2,000 mL

Name

60 g

Country

1,500 mL

40 g

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

Amino acids

1,000 mL

EMEA ARTWORK DESIGN CENTRE

Lipids

Normally, the flow rate must be increased gradually during the first hour and then be adjusted to take
into account the dose being administered, the daily volume intake, and the duration of the infusion.
For TRIOMEL, the maximal infusion rate is 1.7 mL/kg/hour, corresponding to 0.08 g/kg/hour amino acids,
0.24 g/kg/hour glucose, and 0.07 g/kg/hour lipids.
In children greater than 2 years of age
There have been no studies performed in the paediatric population.
The dosage depends on the patient’s energy expenditure, clinical status, body weight, and the ability
to metabolise constituents of TRIOMEL, as well as additional energy or proteins given orally/enterally;
therefore, the bag size should be chosen accordingly.

DRAFT

67

50 – 80

45

2.9

1–2

2.0

12 – 14 (up to 18)

9.3

3 – 10 (up to 14)

6.4

Lipids (g/kg/d)

0.5 – 3

2.7

0.5 – 2 (up to 3)

1.8

Total energy (kcal/kg/d)

60 – 90

76

30 – 75

52

0.20

0.15

0.12

0.12

Glucose (g/kg/h)

1.2

0.46

1.2

0.38

Lipids (g/kg/h)

0.13

0.13

0.13

0.11

Maximum Hourly Rate
TRIOMEL (mL/kg/h)
Amino acids (g/kg/h)

3.3

2.7

a: Recommended values from 2005 ESPGHAN/ESPEN Guidelines
Normally, the flow rate must be increased gradually during the first hour and then be adjusted to take
into account the dose being administered, the daily volume intake, and the duration of the infusion.
In general, it is recommended to start the infusion for small children with low daily dose and gradually
increase it up to the maximal dosage (see above).

Method and duration of administration
For single use only.
It is recommended that, after opening the bag, the contents are used immediately and not stored for
subsequent infusion.
After reconstitution, the mixture is homogenous with a milky appearance.
Due to its high osmolarity, TRIOMEL can only be administered through a central vein.
The recommended duration of infusion for a parenteral nutrition bag is between 12 and 24 hours.

Version: 01
Sign:
Sign:

Treatment with parenteral nutrition may be continued for as long as required by the patient’s clinical
conditions.

Date:
Date:

For instructions for preparation and handling of the emulsion for infusion, see section 6.6 of the SmPC.

9

BE-30-02-812

(and pages ___ to ___ for TIL)

Glucose (g/kg/d)

60 – 120
1 – 2 (up to 3)

Applicable for pages ___ to ___

Amino acids (g/kg/d)

FOR SUBMISSION

Fluids (mL/kg/d)

Date

Maximum Daily Dose

DRAFT

TRIOMEL
Max Vol

Signature

Recommendeda

Name

Recommendeda

12 to 18 years

TRIOMEL
Max Vol

Country

2 to 11 years
Constituent

EMEA ARTWORK DESIGN CENTRE

For TRIOMEL in the 2 to 11 year age group, the limiting factors are phosphate concentration for daily
dose (0.2 mmol/kg/day)a and lipid concentration for hourly rate. In the 12 to 18 year age group, amino
acid concentration is the limiting factor for both daily dose and hourly rate. The resulting intakes are
displayed below:

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

In addition, daily fluid, nitrogen, and energy requirements continuously decrease with age. Two groups,
ages 2 to 11 years and 12 to 18 years, are considered.

C. INCOMPATIBILITIES
Do not add other medicinal products or substances to any components of the bag or to the reconstituted
emulsion without first confirming their compatibility and the stability of the resulting preparation (in
particular, the stability of the lipid emulsion).
Incompatibilities may be produced, for example, by excessive acidity (low pH) or inappropriate content of
divalent cations (Ca2+ and Mg2+), which may destabilize the lipid emulsion.
As with any parenteral nutrition admixture, calcium and phosphate ratios must be considered. Excess
addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of
calcium phosphate precipitates.

DRAFT

Ensure that the product is at room temperature when breaking the nonpermanent seals.
Manually roll the bag onto itself, starting at the top of the bag (hanger end). The nonpermanent seals
will disappear from the side near the inlets. Continue to roll the bag until the seals are open along
approximately half of their length.
Mix by inverting the bag at least 3 times.
After reconstitution, the mixture is a homogeneous emulsion with a milky appearance.

Additions
The capacity of the bag is sufficient to enable additions such as vitamins, electrolytes, and trace
elements.
Any additions (including vitamins) may be made into the reconstituted mixture (after the nonpermanent
seals have been opened and after the contents of the 3 compartments have been mixed).

Version: 01
Sign:
Sign:

When making additions to formulations containing electrolytes, the amount of electrolytes already
present in the bag should be taken into account.

Date:
Date:

Vitamins may also be added into the glucose compartment before the mixture is reconstituted (before
opening the nonpermanent seals and before mixing the 3 compartments).

10

BE-30-02-812

(and pages ___ to ___ for TIL)
Applicable for pages ___ to ___

Mixing the solutions and the emulsion

FOR SUBMISSION

Confirm the integrity of the bag and of the nonpermanent seals. Use only if the bag is not damaged; if
the nonpermanent seals are intact (i.e., no mixture of the contents of the 3 compartments); if the amino
acid solution and the glucose solution are clear, colourless, or slightly yellow, and practically free of
visible particles; and if the lipid emulsion is a homogeneous liquid with a milky appearance.

Date

Discard the oxygen absorber sachet.

DRAFT

Remove the protective overpouch.

Signature

To open

Name

An overview of the preparation steps for the administration of TRIOMEL are provided in Figure 1.

Country

D. SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

EMEA ARTWORK DESIGN CENTRE

Do not administer before, simultaneously with, or after blood through the same equipment because of
the risk of pseudoagglutination.

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

Check compatibility with solutions administered simultaneously through the same administration set,
catheter, or cannula.

Additions must be performed by qualified personnel under aseptic conditions.

5.6 mmol

Calcium

0 mmol

5.0 (3.5a) mmol

5.0 (3.5a) mmol

Inorganic Phosphate

0 mmol

8.0 mmol

8.0 mmol

Organic Phosphate

3 mmolb

22 mmol

25 mmolb

a: Value corresponding to the addition of inorganic phosphate.
b: Including phosphate provided by the lipid emulsion.
Trace elements and vitamins:
Stability has been demonstrated with commercially-available preparations of vitamins and trace
elements (containing up to 1 mg of iron).
Compatibility for other additives is available upon request.
When making additions, the final osmolarity of the mixture must be measured before administration via
a peripheral vein.
To perform an addition:
– Aseptic conditions must be observed.
– Prepare the injection site of the bag.
– Puncture the injection site and inject the additives using an injection needle or a reconstitution
device.
– Mix content of the bag and the additives.

Preparation of the infusion
Aseptic conditions must be observed.
Suspend the bag.
Remove the plastic protector from the administration outlet.
Firmly insert the spike of the infusion set into the administration outlet.
Figure 1: Preparation steps for the administration of TRIOMEL
1.

2.

Tear from the top to open the
overpouch.

4.

3.

Peel the front of the overpouch
to reveal the TRIOMEL bag.
Discard the overpouch and
oxygen absorber sachet.
5.

Lift the hanger area to remove
solution from the upper bag. Roll
the upper part of the bag firmly
until peal seals are fully open
(approximately half way).

Place the bag flat on a
horizontal and clean surface
with the handle in front of you.
6.

Mix by turning the bag
upside-down at least 3 times.

11

Hang the bag. Twist off
the protector from the
administration outlet. Firmly
plug the spike connector.
BE-30-02-812

(and pages ___ to ___ for TIL)

150 mmol

5.6 mmol

Applicable for pages ___ to ___

150 mmol

0 mmol

FOR SUBMISSION

0 mmol

Magnesium

Date

Potassium

DRAFT
DRAFT

150 mmol

Signature

150 mmol

Name

0 mmol

Date:
Date:

Sodium

Country

Maximal total level

Version: 01
Sign:
Sign:

Maximal further
addition

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

Per 1,000 mL
Included level

EMEA ARTWORK DESIGN CENTRE

TRIOMEL may be supplemented with electrolytes according to the table below:

DRAFT

Administration
For single use only.
Only administer the product after the nonpermanent seals between the 3 compartments have been
broken and the contents of the 3 compartments have been mixed.

Version: 01
Sign:
Sign:

Date:
Date:
12

BE-30-02-812

Applicable for pages ___ to ___

The infusion should not be restarted in the same central vein.

FOR SUBMISSION

The extravasation site should be monitored at least every 4 hours during the 24 first hours, then once
daily.

Date

Depending on the extravasated product (including the product(s) being mixed with TRIOMEL, if
applicable) and the stage/extend of any injury, appropriate specific measures should be taken. Options
for management may include non-pharmacologic, pharmacologic and/or surgical intervention. In case of
large extravasation, plastic surgeon advice should be sought within the first 72 hours.

DRAFT

If extravasation occurs, the administration should be stopped immediately, keeping the inserted catheter
or cannula in place for immediate management of the patient. If possible, aspiration should be performed
through the inserted catheter/cannula, in order to reduce the amount of fluid present in the tissues
before removing the catheter/cannula.

Signature

Catheter site should be monitored regularly to identify signs of extravasation.

Name

Extravasation

Country

Any unused product or waste material and all necessary devices must be discarded.

EMEA ARTWORK DESIGN CENTRE

Do not connect bags in series in order to avoid the possibility of air embolism due to gas contained in
the primary bag.

ARTWORK APPROVAL
2nd DRAFT
LAYOUT AND FORMAT
PLANT APPROVAL
APPROVAL
HALLE ONLY

After opening the bag, the contents must be used immediately. The opened bag must never be stored for
a subsequent infusion. Do not reconnect any partially used-bag.

(and pages ___ to ___ for TIL)

Ensure that the final emulsion for infusion does not show any evidence of phase separation.

+ Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide